Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Fallopian Tube Neoplasms
  • Ovarian Neoplasms
  • Paclitaxel
  • Peritoneal Neoplasms

abstract

  • Paclitaxel can be delivered by the IP route on a weekly schedule with both an acceptable toxicity profile and a major pharmacokinetic advantage for cavity exposure. The recommended dose and schedule for phase II study of IP paclitaxel is 60 to 65 mg/m2 weekly.

publication date

  • December 1995

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8523061

Additional Document Info

start page

  • 2961

end page

  • 7

volume

  • 13

number

  • 12